What is LOPJLB’s current signal on IOBT?

LOPJLB’s latest quantitative signal on IO Biotech, Inc. (IOBT) is SELL in a CRISIS regime. Signals are updated daily.

What market regime is IOBT in?

IO Biotech, Inc. (IOBT) is currently classified in the CRISIS HMM market regime on LOPJLB.

What does IO Biotech, Inc. (IOBT) do?

IO Biotech, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating immune-modulating cancer treatments. These therapies leverage its proprietary T-win technology platform. The company's primary investigational drug, IO102-IO103, is engineered to counteract immunosuppressive proteins such as Indoleamine 2,3-dehydrogenase (IDO) and programmed death-ligand (PD-L1). This candidate is…

IO Biotech, Inc. (IOBT)

COMPARE

Healthcare · Biotechnology · NASDAQ · DK

$0.00Close

SELLCRISIS · day 46

[SCORES & PROFILE]

FUND: 9
VALUE: 18
GROWTH: 39
GARP: 0
TYPE: Balanced

Composite of Value · Growth · GARP

ROIC-

REV YoY-

ROE-

EPS YoY-

ROA-86.6%

GROSS

NET

[VALUATION]

P/E TTM-0.02

P/E FWD-

SECTOR PE20.47

INDUSTRY PE13.95

P/B0.90

P/FCF-

EV/EBITDA0.82

EV/EBIT-

PEG-

FCF YIELD-

RISK

INT COV-

D/E159.71

ALTMAN Z-

CURR RATIO2.01

ND/EBITDA-

BETA0.89

FAQ

What is LOPJLB’s current signal on IOBT?: LOPJLB’s latest quantitative signal on IO Biotech, Inc. (IOBT) is SELL in a CRISIS regime. Signals are updated daily.
What market regime is IOBT in?: IO Biotech, Inc. (IOBT) is currently classified in the CRISIS HMM market regime on LOPJLB.
What does IO Biotech, Inc. (IOBT) do?: IO Biotech, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating immune-modulating cancer treatments. These therapies leverage its proprietary T-win technology platform. The company's primary investigational drug, IO102-IO103, is engineered to counteract immunosuppressive proteins such as Indoleamine 2,3-dehydrogenase (IDO) and programmed death-ligand (PD-L1). This candidate is…

IO Biotech, Inc. (IOBT)

Key stats

Prediction markets

FUNDAMENTALS

Company news

FAQ